Drug
Gzr18
Gzr18: highest development phase Phase 3, developed by Gan & Lee Pharmaceuticals.. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Gan & Lee Pharmaceuticals.
Trials
| Drug | Phase | Indication |
|---|---|---|
| GZR18 NCT06778967 | Phase 3 | Type 2 Diabetes Mellitus (T2DM) |
| GZR18 NCT06777238 | Phase 3 | Type 2 Diabetes Mellitus (T2DM) |
| GZR18 injection NCT07292441 | Phase 3 | Overweight or Obesity |
| GZR18 injection NCT07141030 | Phase 1 | Obesity/Overweight |
| GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets NCT07128888 | Phase 1 | Obesity or Overweight |
Latest
No recent events.
Follow Gzr18 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.